Telmisartan: A multifaceted antihypertension drug.

Telmisartan: A multifaceted antihypertension drug. Curr Med Res Opin. 2016 Apr 7;:1-9 Authors: Rizos CV, Elisaf MS Abstract Obesity is often at the cornerstone of cardiovascular disease (CVD) development and progression. Indeed, increased adipose tissue has been associated with higher prevalence of multiple metabolic disorders and comorbidities. Among them, impaired glucose metabolism, hypertension and dyslipidaemia are the most common companions of adiposity. Moreover, the distribution of adipose tissue, visceral versus subcutaneous, differentiates the effects of obesity on the development of CVD. As a result, a comprehensive treatment of overweight patients targeting all associated comorbidities is of paramount importance. Among various antihypertensive drugs, angiotensin receptor blockers (ARBs) have an established efficacy and safety, making them a favourable choice. However, all ARBs do not share the same qualities. Telmisartan, beyond its inherent favourable effects of the ARB class, has shown some additional promising pleiotropic effects. Indeed, telmisartan has been associated with favourable outcomes regarding glucose metabolism, dyslipidaemia as well as adipose tissue redistribution. As a result, hypertensive patients with multiple CVD comorbidities may have additional benefits when treated with telmisartan. PMID: 27052942 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research